Close Menu

NEW YORK – As the broader stock market tanked last week amid fears of a coronavirus pandemic, the shares of companies in the genomics research tools and molecular diagnostics markets were not immune to the selloff.

The awful week for publicly traded stocks pulled the GenomeWeb Index down 7 percent for the month of February. In comparison, the Dow Jones Industrial Average fell 11 percent, the Nasdaq declined 8 percent, and the Nasdaq Biotech Index only dropped 2 percent month over month.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

UK Royal Statistical Society is organizing a working group to develop guidelines for assessing COVID-19 tests, the Guardian reports.

The Washington Post reports that the White House chief of staff has asked the US Food and Drug Administration to justify the stricter standards it is seeking for a coronavirus vaccine.

President Donald Trump's "good genes" comment raises eugenics concerns, CNN reports.

In PLOS this week: genetic analysis of tremor condition, analysis of a West and Central African tree used in traditional medicine, and more.